Form PT	0-1449									1	ATTY DOCKE	T NO.			APPLICAT	ION NO.		
,									0020-4817P APPLICANT ITOH et al.				New 01/763985					
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)														ATTATCH TO THE				
										Filing DATE February 28, 2001			1	GROUP	#	为		
							U	.S. P	ATENT	DO	CUMEN'	rs						
EXAMINER INITIAL	T	DOC	UMEN	1 TV	IMU	BER		DATE			NAME			CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	<u> </u>									十						†		
			П					1			,	,						
										\Box								
	<u> </u>	_	\sqcup		_			<u> </u>		\rightarrow								
	<u> </u>	<u> </u>				<u> </u>										<u> </u>		
							FOI	REIGN	PATEN	N.T. I	OCUME	NTS						
		DOCUMENT NUMBER						I	DATE		COUNTRY	0	CLASS	SUB CLASS		SLATION		
	<u> </u> 	\top				Τ	T	 		\dashv					 	YES	NO	
	 	+	+					 		_						1		
		+-	\vdash		<u> </u>					-								
	<u> </u>	\top	H							十								
OTHER journal, seri	DOCUM	ium, ca	atalog,	, etc.	.) dat	te, pa	ige(s), vol	lume-issue r	number(s), p	publish	ner, city and	icle (when app i/or country w	where publ:	ished.				
	La	Shichijo et al, "A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes" J. Exp. Med, February 2, 1998, Vol. 187, No. 3, pp. 277-288																
	Цb	Gohara "Histocompatibility Leukocyte Antigen-A2402-restricted Cytotoxic T Lymphocytes Recognizing Adenocarcinoma in Tumor-infiltrating Lymphocytes of Patients with Coiono Cancer" Jpn. J. Cancer Res, February 1997, Vol. 88, No. 2, pp. 198-204.																
	LF	Nagase "Prediction of tha Coding sequences of Unidentified Human Genes. IV. Tha Coding of 40 New Genes (KIAA0121-KIAA0160) Deduced by Analysis of cDAN Clones from Human Cell Line KG-1" J. Clin. Invest., August 1995, Vol. 2, No. 4, pp. 167-174.																
	Ą	Yotnda "Cytotoxic T cell Response Against the Chimeric ETV6-AML1 Protein in Childhood Acute Lymphblastic Leukemia" J. Clim. Invest., July 1998, Vol. 102, No. 2, pp. 455-462.																
	M	TAKAHASHI "Recognition of gp43 Tumor-Associated Antigen Peptide by both HLA-A2 Restricted CTL Lines and Antibodiesfrom Melanoma Patients" Cellular Immuunology, June 15, 1997, Vol. 178, No. 2, pp. 162-171.																
EXAMINER		<u> </u>		Mi.	111	1 64	M				DATE CONSI		9/11/	02				
EXAMINER: Ini considered.	tial if cit. Include cor	ation by of t	consid his to	ened,	#het th ne	her o	r not cita mmunicatio	tion is in on to applic	conformance cant.	a with	M.P.E.P. 609	; Draw line t	hrough cit	ation :	if not in co	onformance a	and not	



Sheet 1 of 1 (06/28/01)

										_			
Form PT	0-1449		-			ATTY DOCKET NO. 0020-4817P	09/763,985						
11	NFORMA	TION I			E CITATION ION	ITOH, Kyogo et	ATTOTICA TO						
	(t	Jse severa	l sheet	s if nec	essary)	FILING DATE February 28, 2	UNASSIGNED						
-					U.S. PATENT I	OCUMENTS				_			
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	_			
										=			
FOREIGN PATENT DOCUMENTS													
		DOCUMEN	T NUMI	BER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO	٦			
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.													
CAS.		Rosenberg et al., "Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2"; J.of the Natl.Cancer Inst., Vol.86, No. 15 (August 1994)											
Λe		Rammensee et al., "MHC Ligands and Peptide Motifs: First Listing"; Immunogenetics, Vol.41., pp.178-228 (1995)											
Ten		Kubo et al., "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles"; J. of Immunology, Vol. 152, pp. 3913-3924 (1994)											
2		Kondo et al., "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules"; J. of Immunology, Vol. 155, pp.4307-4312 (1995)											
M		Sudo et al., "Differences in MHC Class I Self peptide Repertoires among HLA-A2 Subtypes"; The J. of Immunology, Vol. 155, pp. 4749-4756 (1995)											
THE		Rivoltini et al., "Induction of Tumor-Reactive CTL from peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1"; The J. of Immunology, Vol. 154,pp. 2257-2265 (1995)											
2		Kharkevitch et al., "Characterization of Autologous Tumor-Specific T-Helper 2 Cells in Tumor-Infiltrating Lymphocytes from a Patient with Metastatic Melanoma"; Int.J.Cancer, Vol. 58, pp.317-323 (1994)											
Jo		Van Tsai et al., "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells"; The J. of Immunology, Vol. 158, pp. 1796-1802 (1997)											
hoo		Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes"; Science, Vol. 274, pp.94-96 (Oct. 1996)											
ma		Nakao et al., "HLA A2601-restricted CTLs Recognize a peptide Antigen Expressed on Squamous Cell Carcinoma"; Cancer Research, Vol. 55, pp. 4248-4252 (Oct. 1995)											
Les		Thomsen et al., "DELIVERY OF MULTIPLE CD8 Cytotoxic T Cell Epitopes by DNA Vaccination"; The J. of Immunology, Vol. 160, pp. 1717-1723 (1998)											
140		KIAA0156 (Genbank Accession No. D63879) 7/10/97											
L(M) EXAMINER	HLA-A2 cDNA (Genbank Accession No. M84379) 17-195 ER DATE CONSIDERED												
		WAR.	1	UNH	<u></u> .	9//	1/02			_			
EXAMINER: Ini	tial if cits	ation consider	ered, whe	ther or no	t citation is in conformance w	with M.P.E.P. 609; Draw line thr	ough citatio	n if not in	conformance and not	Ţ.,			



DIPER

6

APPLICATION NO. ATTY DOCKET NO. Form PTO-1449 0020-4817P 09/763,985 · INFORMATION DISCLOSURE APPLICANT 19 ITOH et al. IN AN APPLICA # 🗶 FILING DATE GROUP (Use several sheets if necessary February 28, 2001 1651 U.S. PATENT DOCUMENTS NAME EXAMINER INITIAL DOCUMENT NUMBER DATE FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER CLASS TRANSLATION DATE COUNTRY PCT WO 00/55174 2000-09-21 [M EP 1 033 401 A2 2000-09-06 EPO OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. TOH et al., Cellular Immunology, Vol. 177, Article No. CI971105, pp. 137-143, (1997). YANG et al., CANCER RESEARCH, Vol. 59, pp. 4056-4063, (1999). W Accession No. HSORF51, "Human mRNA for KIA0156 gene, complete cds.", August 8, 1995, EMBL Database. Accession No. AAGO1853, "Human Secreted protein, SEQ ID NO: 5934.", September 6, H 2000, EMBL Database. DATE CONSIDERED EXAMINER EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.